Insulet Corporation $PODD Stock Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its position in Insulet Corporation (NASDAQ:PODD) by 88.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,107 shares of the medical instruments supplier’s stock after selling 141,890 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Insulet were worth $2,362,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Insulet during the third quarter worth about $2,758,000. ProShare Advisors LLC boosted its holdings in Insulet by 6.0% in the third quarter. ProShare Advisors LLC now owns 20,802 shares of the medical instruments supplier’s stock valued at $2,714,000 after purchasing an additional 1,185 shares during the last quarter. Vise Technologies Inc. boosted its holdings in Insulet by 52.9% in the third quarter. Vise Technologies Inc. now owns 5,503 shares of the medical instruments supplier’s stock valued at $718,000 after purchasing an additional 1,903 shares during the last quarter. International Assets Investment Management LLC grew its stake in Insulet by 61,543.8% during the 3rd quarter. International Assets Investment Management LLC now owns 45,000 shares of the medical instruments supplier’s stock valued at $5,871,000 after purchasing an additional 44,927 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in Insulet by 144.7% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,356 shares of the medical instruments supplier’s stock valued at $3,308,000 after purchasing an additional 14,996 shares in the last quarter.

Insulet Stock Down 6.2%

NASDAQ:PODD opened at $146.51 on Friday. The firm has a market capitalization of $10.16 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.08 and a beta of 1.06. The stock has a 50 day moving average of $141.97 and a 200-day moving average of $176.65. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.24 EPS. Analysts predict that Insulet Corporation will post 6.75 EPS for the current year.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Leerink Partners lifted their price objective on Insulet from $143.00 to $167.00 and gave the stock a “market perform” rating in a report on Thursday. Sanford C. Bernstein raised their price target on shares of Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday. Raymond James Financial reissued an “outperform” rating and set a $180.00 price target on shares of Insulet in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $152.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Truist Financial cut shares of Insulet from a “buy” rating to a “hold” rating and cut their price target for the company from $210.00 to $153.00 in a report on Wednesday, August 5th. Twelve analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $185.38.

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.

Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Insulet serves customers in the United States and international markets.